Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Kathleen E Squires, Benjamin Young, Lizette Santiago, Robin H Dretler, Sharon L Walmsley, Henry H Zhao, Gary E Pakes, Lisa L Ross & Mark S Shaefer. (2017) Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. HIV/AIDS - Research and Palliative Care 9, pages 51-61.
Read now
Read now
Benjamin Young, Kathleen E. Squires, Karen Tashima, Keith Henry, Stefan Schneider, Anthony LaMarca, Henry H. Zhao, Lisa L. Ross & Mark S. Shaefer. (2015) Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clinical Trials 16:4, pages 125-129.
Read now
Read now
Kathleen E. Squires, Benjamin Young, Edwin DeJesus, Nicholaos Bellos, Daniel Murphy, Douglas Ward, Henry H. Zhao, Lisa L. Ross & Mark S. Shaefer. (2012) ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine. HIV Clinical Trials 13:5, pages 233-244.
Read now
Read now
Thomas Rampling & Mark Nelson. (2011) Clinical utility and long-term use of atazanavir in the treatment of HIV-1 infection. Virus Adaptation and Treatment 3, pages 25-34.
Read now
Read now
Articles from other publishers (17)
Veronique Michaud, Lucy I. Darakjian, Pamela Dow & Jacques Turgeon. (2022) Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis. Current Pharmacology Reports 8:2, pages 79-98.
Crossref
Crossref
Malewe Kolou, Armel Poda, Zelica Diallo, Esther Konou, Tatiana Dokpomiwa, Jacques Zoungrana, Mounerou Salou, Lionèle Mba-Tchounga, André Bigot, Abdoul-Salam Ouedraogo, Marielle Bouyout-Akoutet, Didier K. Ekouevi & Serge P. Eholie. (2021) Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa. BMC Immunology 22:1.
Crossref
Crossref
Lisa L. Ross, A. Sarah Walker, Yu Lou, Allan R. Tenorio, Diana M. Gibb, Julia Double, Charles Gilks, Cynthia C. McCoig, Paula Munderi, Godfrey Musoro, Cissy M. Kityo, Heiner Grosskurth, James Hakim, Peter N. Mugyenyi, Amy Cutrell, Teodora Perger & Mark S. Shaefer. (2019) Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min. PLOS ONE 14:11, pages e0225199.
Crossref
Crossref
Chris M. Stainsby, Teodora M. Perger, Vani Vannappagari, Karam C. Mounzer, Ricky K. Hsu, Cassidy E. Henegar, James Oyee, Rimgaile Urbaityte, Charlotte E. Lane, Lindsay M. Carter, Gary E. Pakes & Mark S. Shaefer. (2018)
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of
HLA
‐B*5701 Screening as a Risk‐Mitigation Measure
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39:1, pages 40-54.
Crossref
Crossref
Catherine Butkus Small, David A. Margolis, Mark S. Shaefer & Lisa L. Ross. (2017) HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infectious Diseases 17:1.
Crossref
Crossref
Torsak Bunupuradah, Sasisopin Kiertiburanakul, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Malee Techapornroong, Niramon Leerattanapetch, Pacharee Kantipong, Chureeratana Bowonwatanuwong, Sukit Banchongkit, Virat Klinbuayaem, Sripetcharat Mekviwattanawong, Sireethorn Nimitvilai, Supunnee Jirajariyavej, Wisit Prasithsirikul, Warangkana Munsakul, Sorakij Bhakeecheep, Suchada Chaivooth, Praphan Phanuphak, David A Cooper, Tanakorn Apornpong, Stephen J Kerr, Sean Emery & Kiat Ruxrungtham. (2016) Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial. The Lancet HIV 3:8, pages e343-e350.
Crossref
Crossref
Eugen BrailoiuElena DeliuRomeo A. SporiciKhalid Benamar & G. Cristina Brailoiu. (2014) HIV-1-Tat excites cardiac parasympathetic neurons of nucleus ambiguus and triggers prolonged bradycardia in conscious rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 306:11, pages R814-R822.
Crossref
Crossref
Frederick J. Lee, Janaki Amin & Andrew Carr. (2014) Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up. PLoS ONE 9:5, pages e97482.
Crossref
Crossref
Michael O'Kelly & Bohdana RatitchSara Hughes. 2014. Clinical Trials with Missing Data. Clinical Trials with Missing Data
36
52
.
Michael O'Kelly & Bohdana Ratitch. 2014. Clinical Trials with Missing Data. Clinical Trials with Missing Data
409
421
.
Lisa L. Ross, Joseph Horton, Samiul Hasan, James R. Brown, Daniel Murphy, Edwin DeJesus, Martin Potter, Anthony LaMarca, Ivan Melendez-Rivera, Douglas Ward, Jonathon Uy & Mark S. Shaefer. (2014) HIV-1 Transmission Patterns in Antiretroviral Therapy-Naïve, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing. PLoS ONE 9:2, pages e89611.
Crossref
Crossref
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Crossref
Michael A. Martin & Deanna L. Kroetz. (2013) Abacavir Pharmacogenetics - From Initial Reports to Standard of Care. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:7, pages 765-775.
Crossref
Crossref
Benjamin YoungKathleen E. SquiresLisa L. RossLizette SantiagoLouis M. SloanHenry H. ZhaoBrian C. WineGary E. PakesDavid A. MargolisMark S. Shaefer, for the ARIES (EPZ108859). (2013) Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without Ritonavir in ARIES. AIDS Research and Human Retroviruses 29:2, pages 350-358.
Crossref
Crossref
Sara Hughes, Julia Harris, Nancy Flack & Robert L. Cuffe. (2012) The statistician's role in the prevention of missing data. Pharmaceutical Statistics 11:5, pages 410-416.
Crossref
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Crossref
Chad J Achenbach, Kristin M Darin, Robert L Murphy & Christine Katlama. (2011) Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virology 6:2, pages 157-177.
Crossref
Crossref